AAPL316.22-3.75 (-1.17%) ▼|ABBV248.78-7.68 (-2.99%) ▼|ABT105.52-2.81 (-2.59%) ▼|ACN179.03-7.69 (-4.12%) ▼|ADBE257.26-9.25 (-3.47%) ▼|AMAT472.79+18.08 (+3.98%) ▲|AMD505.74+28.17 (+5.90%) ▲|AMGN393.17-44.06 (-10.08%) ▼|AMT175.73-0.12 (-0.07%) ▼|AMZN256.97-1.54 (-0.60%) ▼|AVGO368.56+10.67 (+2.98%) ▲|AXP326.10-0.06 (-0.02%) ▼|BA210.73-1.52 (-0.72%) ▼|BAC62.39-0.29 (-0.46%) ▼|BKNG180.30-12.99 (-6.72%) ▼|BLK1,095.37-21.19 (-1.90%) ▼|BMY64.69-2.13 (-3.19%) ▼|BNY162.85-1.99 (-1.21%) ▼|BRK-B505.83-0.20 (-0.04%) ▼|C136.74-0.98 (-0.71%) ▼|CAT822.48+8.54 (+1.05%) ▲|CL88.41-0.36 (-0.41%) ▼|CMCSA26.33-0.16 (-0.60%) ▼|COF213.96-5.64 (-2.57%) ▼|COP135.04+0.78 (+0.58%) ▲|COST910.18-5.56 (-0.61%) ▼|CRM249.12-10.11 (-3.90%) ▼|CSCO109.17-0.03 (-0.03%) ▼|CVS96.07-0.67 (-0.69%) ▼|CVX209.80+1.20 (+0.58%) ▲|DE680.73-12.80 (-1.85%) ▼|DHR205.23-2.43 (-1.17%) ▼|DIS105.06-0.25 (-0.24%) ▼|DUK121.24+1.02 (+0.85%) ▲|EMR152.15-0.67 (-0.44%) ▼|FDX314.13-8.39 (-2.60%) ▼|GD356.58-2.81 (-0.78%) ▼|GE334.91-2.21 (-0.66%) ▼|GEV971.31+29.36 (+3.12%) ▲|GILD146.64-4.36 (-2.88%) ▼|GM85.79-1.97 (-2.24%) ▼|GOOG335.38+0.07 (+0.02%) ▲|GOOGL338.36-0.10 (-0.03%) ▼|GS1,036.53-2.08 (-0.20%) ▼|HD313.70-7.35 (-2.29%) ▼|HON208.24-1.37 (-0.65%) ▼|IBM232.09-2.80 (-1.19%) ▼|INTC104.47+8.67 (+9.05%) ▲|INTU318.93-13.77 (-4.14%) ▼|ISRG350.16-16.54 (-4.51%) ▼|JNJ269.12-6.11 (-2.22%) ▼|JPM353.51-5.13 (-1.43%) ▼|KO88.36+0.29 (+0.33%) ▲|LIN468.38-9.19 (-1.92%) ▼|LLY1,123.91-25.45 (-2.21%) ▼|LMT536.15+10.87 (+2.07%) ▲|LOW200.80-3.65 (-1.79%) ▼|LRCX320.42+12.77 (+4.15%) ▲|MA570.89-8.32 (-1.44%) ▼|MCD255.81+0.12 (+0.05%) ▲|MDLZ61.63+0.35 (+0.57%) ▲|MDT92.39-1.78 (-1.89%) ▼|META613.48-3.29 (-0.53%) ▼|MMM167.52-1.04 (-0.62%) ▼|MO68.17-0.71 (-1.03%) ▼|MRK148.46-1.87 (-1.24%) ▼|MS216.24-1.48 (-0.68%) ▼|MSFT493.95-5.75 (-1.15%) ▼|MU1,000.26-16.33 (-1.61%) ▼|NEE83.83+0.40 (+0.48%) ▲|NFLX76.77-1.48 (-1.89%) ▼|NKE38.10-0.30 (-0.78%) ▼|NOW134.21-7.05 (-4.99%) ▼|NVDA225.73-4.63 (-2.01%) ▼|ORCL162.52+3.74 (+2.36%) ▲|PEP138.45+0.82 (+0.60%) ▲|PFE27.79-0.66 (-2.32%) ▼|PG145.58-0.86 (-0.59%) ▼|PLTR170.30-4.03 (-2.31%) ▼|PM184.73+2.20 (+1.21%) ▲|QCOM174.09+5.35 (+3.17%) ▲|RTX198.81-1.98 (-0.99%) ▼|SBUX102.01-2.46 (-2.35%) ▼|SCHW106.87-2.42 (-2.21%) ▼|SO88.99+0.88 (+1.00%) ▲|SPG211.88+2.44 (+1.17%) ▲|T25.60-0.08 (-0.31%) ▼|TMO603.02-10.76 (-1.75%) ▼|TMUS181.69+0.17 (+0.09%) ▲|TSLA368.16+14.08 (+3.98%) ▲|TXN258.92+0.48 (+0.19%) ▲|UBER73.13-2.63 (-3.47%) ▼|UNH400.84+3.70 (+0.93%) ▲|UNP288.45-1.17 (-0.40%) ▼|UPS100.48-1.81 (-1.77%) ▼|USB62.49-0.88 (-1.39%) ▼|V368.64-6.43 (-1.71%) ▼|VZ50.41+0.27 (+0.54%) ▲|WFC87.96-2.01 (-2.23%) ▼|WMT106.05-1.09 (-1.02%) ▼|XOM160.66+1.19 (+0.75%) ▲|AAPL316.22-3.75 (-1.17%) ▼|ABBV248.78-7.68 (-2.99%) ▼|ABT105.52-2.81 (-2.59%) ▼|ACN179.03-7.69 (-4.12%) ▼|ADBE257.26-9.25 (-3.47%) ▼|AMAT472.79+18.08 (+3.98%) ▲|AMD505.74+28.17 (+5.90%) ▲|AMGN393.17-44.06 (-10.08%) ▼|AMT175.73-0.12 (-0.07%) ▼|AMZN256.97-1.54 (-0.60%) ▼|AVGO368.56+10.67 (+2.98%) ▲|AXP326.10-0.06 (-0.02%) ▼|BA210.73-1.52 (-0.72%) ▼|BAC62.39-0.29 (-0.46%) ▼|BKNG180.30-12.99 (-6.72%) ▼|BLK1,095.37-21.19 (-1.90%) ▼|BMY64.69-2.13 (-3.19%) ▼|BNY162.85-1.99 (-1.21%) ▼|BRK-B505.83-0.20 (-0.04%) ▼|C136.74-0.98 (-0.71%) ▼|CAT822.48+8.54 (+1.05%) ▲|CL88.41-0.36 (-0.41%) ▼|CMCSA26.33-0.16 (-0.60%) ▼|COF213.96-5.64 (-2.57%) ▼|COP135.04+0.78 (+0.58%) ▲|COST910.18-5.56 (-0.61%) ▼|CRM249.12-10.11 (-3.90%) ▼|CSCO109.17-0.03 (-0.03%) ▼|CVS96.07-0.67 (-0.69%) ▼|CVX209.80+1.20 (+0.58%) ▲|DE680.73-12.80 (-1.85%) ▼|DHR205.23-2.43 (-1.17%) ▼|DIS105.06-0.25 (-0.24%) ▼|DUK121.24+1.02 (+0.85%) ▲|EMR152.15-0.67 (-0.44%) ▼|FDX314.13-8.39 (-2.60%) ▼|GD356.58-2.81 (-0.78%) ▼|GE334.91-2.21 (-0.66%) ▼|GEV971.31+29.36 (+3.12%) ▲|GILD146.64-4.36 (-2.88%) ▼|GM85.79-1.97 (-2.24%) ▼|GOOG335.38+0.07 (+0.02%) ▲|GOOGL338.36-0.10 (-0.03%) ▼|GS1,036.53-2.08 (-0.20%) ▼|HD313.70-7.35 (-2.29%) ▼|HON208.24-1.37 (-0.65%) ▼|IBM232.09-2.80 (-1.19%) ▼|INTC104.47+8.67 (+9.05%) ▲|INTU318.93-13.77 (-4.14%) ▼|ISRG350.16-16.54 (-4.51%) ▼|JNJ269.12-6.11 (-2.22%) ▼|JPM353.51-5.13 (-1.43%) ▼|KO88.36+0.29 (+0.33%) ▲|LIN468.38-9.19 (-1.92%) ▼|LLY1,123.91-25.45 (-2.21%) ▼|LMT536.15+10.87 (+2.07%) ▲|LOW200.80-3.65 (-1.79%) ▼|LRCX320.42+12.77 (+4.15%) ▲|MA570.89-8.32 (-1.44%) ▼|MCD255.81+0.12 (+0.05%) ▲|MDLZ61.63+0.35 (+0.57%) ▲|MDT92.39-1.78 (-1.89%) ▼|META613.48-3.29 (-0.53%) ▼|MMM167.52-1.04 (-0.62%) ▼|MO68.17-0.71 (-1.03%) ▼|MRK148.46-1.87 (-1.24%) ▼|MS216.24-1.48 (-0.68%) ▼|MSFT493.95-5.75 (-1.15%) ▼|MU1,000.26-16.33 (-1.61%) ▼|NEE83.83+0.40 (+0.48%) ▲|NFLX76.77-1.48 (-1.89%) ▼|NKE38.10-0.30 (-0.78%) ▼|NOW134.21-7.05 (-4.99%) ▼|NVDA225.73-4.63 (-2.01%) ▼|ORCL162.52+3.74 (+2.36%) ▲|PEP138.45+0.82 (+0.60%) ▲|PFE27.79-0.66 (-2.32%) ▼|PG145.58-0.86 (-0.59%) ▼|PLTR170.30-4.03 (-2.31%) ▼|PM184.73+2.20 (+1.21%) ▲|QCOM174.09+5.35 (+3.17%) ▲|RTX198.81-1.98 (-0.99%) ▼|SBUX102.01-2.46 (-2.35%) ▼|SCHW106.87-2.42 (-2.21%) ▼|SO88.99+0.88 (+1.00%) ▲|SPG211.88+2.44 (+1.17%) ▲|T25.60-0.08 (-0.31%) ▼|TMO603.02-10.76 (-1.75%) ▼|TMUS181.69+0.17 (+0.09%) ▲|TSLA368.16+14.08 (+3.98%) ▲|TXN258.92+0.48 (+0.19%) ▲|UBER73.13-2.63 (-3.47%) ▼|UNH400.84+3.70 (+0.93%) ▲|UNP288.45-1.17 (-0.40%) ▼|UPS100.48-1.81 (-1.77%) ▼|USB62.49-0.88 (-1.39%) ▼|V368.64-6.43 (-1.71%) ▼|VZ50.41+0.27 (+0.54%) ▲|WFC87.96-2.01 (-2.23%) ▼|WMT106.05-1.09 (-1.02%) ▼|XOM160.66+1.19 (+0.75%) ▲|
22.7 C
New York
Wednesday, September 9, 2026

Tag: patient

newssourceFORcompanyinformationcontent1releasesmarket

New Dr. Wael Sakr Scholarship Launches to Support Aspiring Medical Students

Essay-based award honors Dean Wael Sakr's achievements and commitment to medical education and research; applications open now through April 15, 2027 
Essay-based award honors Dean Wael Sakr's achievements and commitment to medical education and research; applications open now through April 15, 2027

World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market

Sheba Medical Center, which is ranked the #7 hospital in the world,...

Spire Healthcare announced as exclusive Team GB Official Healthcare Services Partner

Spire Healthcare announces a strategic partnership with Team GB, becoming Official Healthcare Services Partner including the Los Angeles 2028 Olympic Games

Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test

Approval expands access to Castle's precision medicine test designed to guide systemic treatment decision making in patients with moderate-to-severe atopic dermatitisFRIENDSWOOD, Texas, July 14,...

Notice of Data Security Event

LEWES, Del., June 26, 2026 /PRNewswire/ -- Women's Wellness of Southern Delaware ("WWSD") is notifying individuals of a data security incident that may have...

Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results

LIKMEZ® (ATI-1501) commercial momentum building in U.S. market

US$40 million NIAID award supporting VXV-01 advancement through Phase 1

Acibadem Healthcare Group Strengthens Global Patient Services Through Multidisciplinary Care and Advanced Medical Technologies

International patients gain access to coordinated medical expertise, advanced treatment options, and personalized support across Acibadem hospitals in Türkiye. 
International patients gain access to coordinated medical expertise, advanced treatment options, and personalized support across Acibadem hospitals in Türkiye.

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval includes a...

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, June 26, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on June 19, 2026, the Organization and Compensation Committee of...

Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of...

WILMETTE, Ill., June 26, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that new analyses from the Phase 3 FoCus randomized controlled clinical trial of ALXN1840 (tiomolibdate choline, TMC) will be presented at the 12th Congress of the European Academy of Neurology (EAN 2026), June 27–30, 2026, in Geneva, Switzerland. These analyses build upon the previously reported Phase 3 FoCus results demonstrating ALXN1840 met its primary endpoint of superior copper mobilization versus standard of care.

Lantheus Receives Complete Response Letter from FDA for LNTH-2501 (Ga 68 edotreotide)

BEDFORD, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for LNTH-2501 (Gallium 68 edotreotide), a PET diagnostic imaging kit targeting somatostatin receptor-positive (SSTR+) neuroendocrine tumors (NETs). 

Daniel D. King, DNP, Selected as a Fellow of the American Academy of Nursing

NORTH CHICAGO, Ill., June 26, 2026 /PRNewswire/ -- Daniel D. King, DNP, CRNA, CPPS, CNE, FNAP, associate professor in the Nurse Anesthesia Program at Rosalind...

The Inner Circle acknowledges Dr. Barbara Betancourt Cortes as a Pinnacle Lifetime Member

ROSWELL, Ga., June 26, 2026 /PRNewswire/ -- Dr. Barbara Betancourt Cortes is Recognized as a Pinnacle Lifetime Member for Excellence in Chiropractic Care and...

Johnson & Johnson presents new IMAAVY®▼ (nipocalimab) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalised myasthenia gravis

BEERSE, BELGIUM, June 26, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new data across 12 abstracts at the European Academy of Neurology (EAN) 2026 Congress that offer additional insight into the use of IMAAVY®▼(nipocalimab) throughout clinically relevant points in the generalised myasthenia gravis (gMG) treatment journey. The analyses include adults with anti-AChRa or anti-MuSKb antibody-positive gMG who were early in their disease course or had lower baseline symptom burden – providing insight into the potential importance of addressing pathogenic immunoglobulin G (IgG) early in disease progression where use of advanced therapies may be less common.1,2 Additional research to be shared include outcomes shortly after common infections, which are a known cause of disease exacerbations in gMG, and plans to address evidence gaps in the use of nipocalimab during pregnancy.3,4

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPatient

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers